The US Department of Health and Human Services has terminated 22 mRNA vaccine research contracts under BARDA, signaling a ...

The biotech company extends its Phase I trial (NCT06252220) of DA-1726 to eight weeks following encouraging early efficacy, ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

Following positive Phase IIb TACTI-003 data, the FDA has endorsed further evaluation of Immutep’s efti-Keytruda combination in first-line recurrent/metastatic HNSCC patients with PD-L1 CPS <1, a ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, discusses how ...

As clinical trials become more complex, success depends on early collaboration, thoughtful protocol design, and practical ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, explains how ...

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...

The Phase I/II trial will evaluate the safety and early efficacy of ABT-301 in combination with tislelizumab and bevacizumab ...

In this video interview, Michael Miller, chief operating officer at Quanterix, discusses how biopharma companies—especially ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...